<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MGH Center for Women's Mental Health &#187; Uncategorized</title>
	<atom:link href="http://www.womensmentalhealth.org/posts/category/uncategorized/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.womensmentalhealth.org</link>
	<description>MGH Center for Women's Mental Health</description>
	<lastBuildDate>Thu, 26 Jan 2012 22:43:39 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>SSRIs and PPHN:  The FDA Revises Its Warning</title>
		<link>http://www.womensmentalhealth.org/posts/ssris-and-pphn-the-fda-revises-its-warning/</link>
		<comments>http://www.womensmentalhealth.org/posts/ssris-and-pphn-the-fda-revises-its-warning/#comments</comments>
		<pubDate>Tue, 17 Jan 2012 19:29:30 +0000</pubDate>
		<dc:creator>MGH Center for Women's Mental Health</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[center for women's mental health]]></category>
		<category><![CDATA[Infants exposed to SSRIs]]></category>
		<category><![CDATA[medication during pregnancy]]></category>
		<category><![CDATA[Pregnancy]]></category>
		<category><![CDATA[SSRIs]]></category>

		<guid isPermaLink="false">http://www.womensmentalhealth.org/?p=1919</guid>
		<description><![CDATA[In 2006, Chambers and colleagues published an article in the New England Journal of Medicine linking SSRI use during late pregnancy to an increased risk of persistent pulmonary hypertension in the newborn (PPHN).   Based on these findings, the “Usage in Pregnancy” section on the labels for SRRI antidepressants was updated to include the following warning: “Infants exposed [...]]]></description>
		<wfw:commentRss>http://www.womensmentalhealth.org/posts/ssris-and-pphn-the-fda-revises-its-warning/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Antidepressant Treatment During Pregnancy: One Woman’s Experience (Part IV)</title>
		<link>http://www.womensmentalhealth.org/posts/antidepressant-treatment-during-pregnancy-one-woman%e2%80%99s-experience-part-iv/</link>
		<comments>http://www.womensmentalhealth.org/posts/antidepressant-treatment-during-pregnancy-one-woman%e2%80%99s-experience-part-iv/#comments</comments>
		<pubDate>Tue, 18 Oct 2011 22:02:04 +0000</pubDate>
		<dc:creator>MGH Center for Women's Mental Health</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[center for women's mental health]]></category>
		<category><![CDATA[Depression]]></category>
		<category><![CDATA[Pregnancy]]></category>
		<category><![CDATA[SSRIs]]></category>

		<guid isPermaLink="false">http://www.womensmentalhealth.org/?p=1760</guid>
		<description><![CDATA[Part 4:  The Postpartum Period This is a continuation of the case presented in a previous post. After discussing the risks and benefits of staying on fluoxetine after delivery versus changing to venlafaxine ER, Ms. D decided to resume venlafaxine ER while remaining on fluoxetine.  Like her previous experiences with venlafaxine ER, she responded quickly [...]]]></description>
		<wfw:commentRss>http://www.womensmentalhealth.org/posts/antidepressant-treatment-during-pregnancy-one-woman%e2%80%99s-experience-part-iv/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sleep Medications:  What Information Do We Have on Reproductive Safety?</title>
		<link>http://www.womensmentalhealth.org/posts/sleep-medications-what-information-do-we-have-on-reproductive-safety/</link>
		<comments>http://www.womensmentalhealth.org/posts/sleep-medications-what-information-do-we-have-on-reproductive-safety/#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:04:06 +0000</pubDate>
		<dc:creator>MGH Center for Women's Mental Health</dc:creator>
				<category><![CDATA[Pregnancy]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[center for women's mental health]]></category>
		<category><![CDATA[medication safety]]></category>
		<category><![CDATA[sleep]]></category>

		<guid isPermaLink="false">http://www.womensmentalhealth.org/?p=1706</guid>
		<description><![CDATA[It is estimated that up to 95% of women experience some type of sleep disturbance during pregnancy.  While for many women the insomnia is relatively benign and may respond to simple interventions, other women experience more severe insomnia which has a significant impact on their quality of life and ability to function.  Various non-benzodiazepine hypnotic [...]]]></description>
		<wfw:commentRss>http://www.womensmentalhealth.org/posts/sleep-medications-what-information-do-we-have-on-reproductive-safety/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Choice of Antidepressant May Affect Survival in Women on Tamoxifen for Breast Cancer</title>
		<link>http://www.womensmentalhealth.org/posts/choice-of-antidepressant-may-affect-survival-in-women-on-tamoxifen-for-breast-cancer/</link>
		<comments>http://www.womensmentalhealth.org/posts/choice-of-antidepressant-may-affect-survival-in-women-on-tamoxifen-for-breast-cancer/#comments</comments>
		<pubDate>Mon, 02 May 2011 13:54:19 +0000</pubDate>
		<dc:creator>MGH Center for Women's Mental Health</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[CYP2D6 inhibitors]]></category>
		<category><![CDATA[selective estrogen receptor modulator]]></category>
		<category><![CDATA[SSRI]]></category>
		<category><![CDATA[Tamoxifen]]></category>
		<category><![CDATA[women's mental health]]></category>

		<guid isPermaLink="false">http://www.womensmentalhealth.org/?p=1624</guid>
		<description><![CDATA[Tamoxifen is a SERM (selective estrogen receptor modulator) used in women with breast cancer; it reduces the risk of relapse and improves overall survival.  Tamoxifen may also be used to reduce the risk of breast cancer in women at high risk for the disease. In order to be fully effective, tamoxifen must be metabolized to [...]]]></description>
		<wfw:commentRss>http://www.womensmentalhealth.org/posts/choice-of-antidepressant-may-affect-survival-in-women-on-tamoxifen-for-breast-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making Individual Decisions Regarding the Use of Antidepressants During Pregnancy</title>
		<link>http://www.womensmentalhealth.org/posts/making-individual-decisions-regarding-the-use-of-antidepressants-during-pregnancy/</link>
		<comments>http://www.womensmentalhealth.org/posts/making-individual-decisions-regarding-the-use-of-antidepressants-during-pregnancy/#comments</comments>
		<pubDate>Mon, 14 Mar 2011 19:19:33 +0000</pubDate>
		<dc:creator>MGH Center for Women's Mental Health</dc:creator>
				<category><![CDATA[Psychiatric Disorders During Pregnancy]]></category>
		<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.womensmentalhealth.org/?p=1576</guid>
		<description><![CDATA[Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy.  This choice can be especially difficult for women taking newer medications which lack adequate reproductive safety data. It is not uncommon for women on newer medications with less reproductive safety data available to attempt to change to a better studied [...]]]></description>
		<wfw:commentRss>http://www.womensmentalhealth.org/posts/making-individual-decisions-regarding-the-use-of-antidepressants-during-pregnancy/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
	</channel>
</rss>

